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Abstract. Cerebral  venous  and  dural
spectrum of clinical presentations. The epidemiology of the disease has evolved considerably during 
the recent decades with increasing oral contraceptive use in  young and middle
has various causes including genetic and acquired prothrombotic disorders and it usually has a 
favorable  outcome  with  a  low  rate  of  thrombotic  recurrence  and  mortality.  Geographical  and 
ethnic variations between populations may result in different distribution 
to  different  pathophysiological  mechanisms  and  clinical  presentations.  In  CVT  series  reported 
mostly  from  the  Americas  and  the  western  European  countries  Behçet’s  disease  (BD)  is  not 
reported as a common cause of CVT. However it c
BD series. Due to the high prevalence of BD in the southeast Mediterranean region BD is a frequent 
cause  of  CVT  in  the area.  Discerning  characteristics  of  patients  with  BD  and  CVT have  been 
reported  previously  and  these  might  be  helpful  in  guiding  diagnosis  and  treatment  of  CVT 
especially in this part of the world.
Cerebral  venous  and  dural sinus  thrombosis  (CVT) 
presents with a broad spectrum of symptoms, and it is 
caused  by  a  variety  of  etiologies.
1-2
CVT cases have a prothrombotic risk factor or a direct 
causative disorder. These include genetic and acquired 
prothrombotic disorders,  cancer,  hematological 
diseases,  pregnancy  and  puerperium,  systemic 
inflammatory  diseases,  neurosurgical  procedures  and 
some local anatomical causes such as ear, head or
infections.  Around  40%  of  CVT  patients  have  more 
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Cerebral  venous  and  dural sinus  thrombosis  (CVT)  is  a  rare  condition  with  a  wide 
spectrum of clinical presentations. The epidemiology of the disease has evolved considerably during 
the recent decades with increasing oral contraceptive use in  young and middle
arious causes including genetic and acquired prothrombotic disorders and it usually has a 
favorable  outcome  with  a  low  rate  of  thrombotic  recurrence  and  mortality.  Geographical  and 
ethnic variations between populations may result in different distribution of CVT etiologies leading 
to  different  pathophysiological  mechanisms  and  clinical  presentations.  In  CVT  series  reported 
mostly  from  the  Americas  and  the  western  European  countries  Behçet’s  disease  (BD)  is  not 
reported as a common cause of CVT. However it can be discerned as a frequent cause of CVT in 
BD series. Due to the high prevalence of BD in the southeast Mediterranean region BD is a frequent 
cause  of  CVT  in  the area.  Discerning  characteristics  of  patients  with  BD  and  CVT have  been 
and  these  might  be  helpful  in  guiding  diagnosis  and  treatment  of  CVT 
especially in this part of the world.
sinus  thrombosis  (CVT) 
presents with a broad spectrum of symptoms, and it is 
Nearly  85%  of 
CVT cases have a prothrombotic risk factor or a direct 
causative disorder. These include genetic and acquired 
disorders,  cancer,  hematological 
diseases,  pregnancy  and  puerperium,  systemic 
inflammatory  diseases,  neurosurgical  procedures  and 
tomical causes such as ear, head or neck 
infections.  Around  40%  of  CVT  patients  have  more 
than  one  risk  factor.
3
inflammatory disorders, systemic lupus erythematotsus 
(SLE),  antiphospholipid  syndrome,  sarcoidosis  and 
Behcet’s disease (BD) can be listed. 
CVT  affects  approximately  5  people  per  million 
annually.
4 Although  underlying  factors  may  be
common with other types of venous thromboembolism, 
the unique way the central nervous system is affected 
with  CVT  gives  it  an  exceptional  place  under  the 
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sinus  thrombosis  (CVT)  is  a  rare  condition  with  a  wide 
spectrum of clinical presentations. The epidemiology of the disease has evolved considerably during 
the recent decades with increasing oral contraceptive use in  young and middle-aged women. CVT 
arious causes including genetic and acquired prothrombotic disorders and it usually has a 
favorable  outcome  with  a  low  rate  of  thrombotic  recurrence  and  mortality.  Geographical  and 
of CVT etiologies leading 
to  different  pathophysiological  mechanisms  and  clinical  presentations.  In  CVT  series  reported 
mostly  from  the  Americas  and  the  western  European  countries  Behçet’s  disease  (BD)  is  not 
an be discerned as a frequent cause of CVT in 
BD series. Due to the high prevalence of BD in the southeast Mediterranean region BD is a frequent 
cause  of  CVT  in  the area.  Discerning  characteristics  of  patients  with  BD  and  CVT have  been 
and  these  might  be  helpful  in  guiding  diagnosis  and  treatment  of  CVT 
Among  the  systemic 
inflammatory disorders, systemic lupus erythematotsus 
(SLE),  antiphospholipid  syndrome,  sarcoidosis  and 
Behcet’s disease (BD) can be listed. 
CVT  affects  approximately  5  people  per  million 
Although  underlying  factors  may  be
common with other types of venous thromboembolism, 
the unique way the central nervous system is affected 
with  CVT  gives  it  an  exceptional  place  under  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
concept of venous thrombosis. Even though CVT can 
develop in the course of various disorders, due to its 
clinical presentation most of the patients are evaluated 
within stroke cohorts. CVT accounts for 0.5 to 1% of 
all  strokes.
2,4 In  Istanbul  Medical  School  Stroke 
Registry CVT comprises 1% of all strokes.
5 It is hard 
to estimate the number of CVT cases associated with 
various etiological processes that are not included in 
stroke  registries.  The  largest  information  on  CVT  is 
provided by International Study on Cerebral Vein and 
Dural  Sinus  Thrombosis  (ISCVT)  comprised  of  624 
cases. In that prospective observational study, aimed to 
determine prognosis of CVT, 624 symptomatic  CVT 
cases from 21 countries were registered over 3 years 
and ample information about all characteristics of CVT 
patients were obtained as well.  Fifty-seven percent of 
these  cases  are  from North-western  Mediterranean 
countries (France, Portugal, Spain and Italy). Overall 
74.5% of patients were women and in 2/3rds of them 
CVT was associated with pregnancy, puerperium, oral 
contraceptives (OC) or hormone replacement  therapy 
(HRT);  factors  associated  with  gender.  The  second 
most  common  etiological  factor  was  thrombophilia 
with  a  rate  of  34%.  However,  these  figures  do  not 
reflect  the  true  underlying  factor  incidence  since  in 
more than 40 % of the cases there was more than one 
risk factor. 
Information  on  epidemiology  and  risk  factors  for 
cerebral  venous  thrombosis  (CVT)  in  North-western 
Mediterranean countries are largely available. On the 
contrary,  information  on  CVT  in  the  South-eastern 
Mediterranean region is relatively sparse.  The aim of 
this  review  is  to  focus  on  CVT  and  inherited  and 
acquired  causes  in  countries  of  the  South-eastern 
Mediterranean region. 
Behcet’s  disease  is  one  of  the  systemic 
inflammatory  diseases  with  high  risk  of  venous 
thromboembolism and it is seen more commonly along 
the  Silk  Route  that  extends  from  the  Mediterranean 
region  to  Japan.
6 In the  South-eastern Mediterranean 
region etiology of CVT differs compared to Western 
countries,  due  to  the  higher  prevalence  of  Behcet’s 
disease in  the region.  Behcet’s disease is  a  systemic 
inflammatory  disorder  of  unknown  etiology,  which 
presents with recurrent oral aphtae, genital ulcerations, 
and  uveitis.  Diagnostic  criteria  for  BD  are  listed  on 
Table 1.
7 Central nervous system (CNS) involvement 
is seen about in 5-10% of cases with BD.
8-9 Besides the 
more  commonly  encountered  parenchymal 
neurological  involvement  which  occurs  mainly  as  a 
brainstem  meningoencephalitis,  intracranial 
hypertension due to CVT may be seen in about 15% of 
the  patients  with  neurological  involvement.  In  our 
series  this  ratio  was  17%,  in  another  series  from 
Tunisia it was 11%.
10-11
Although population based studies are lacking from 
South-eastern  Mediterranean  countries,  a  previous 
study  comparing  a  series  of  CVT  patients  with  and 
without BD revealed that more than half of the patients 
diagnosed  with  CVT  have  BD  as  the  underlying 
factor.
12 When  the  yearly  rate  of  CVT  patients  are 
compared according to etiology in this cohort 42% of 
the patients had BD as the causative factor compared to 
all other etiologies complied as a separate group as the 
underlying  conditions  for  the  remaining  58%.
12 One 
point  deserves  further  clarification  because  in  this 
study, non-BD group consisted largely of patients that 
were  admitted  to  the  hospital  with  CVT;  however, 
there  may  be  another  group of  patients  who  present 
with  isolated  ICH  symptoms  or  only  headache  that 
were either not diagnosed as CVT or were diagnosed 
but managed in the emergency room due to relatively 
less  serious  clinical  presentation  and  consequently 
were not included in the database. 
Behcet’s disease comprises a significant portion of 
CVT  cases  from  many  Mediterranean  countries, 
although  the  percentage  varies  according  to  the 
country, and the center reporting the series. A series 
from  France  analyzing  isolated  intracranial 
hypertension as the only sign of CVT found that these 
patients consisted as high as 37% of all CVT patients 
and  22%  of  them  had  BD  as  the  underlying  cause; 
however, this center is one of the dedicated centers to 
Behcet’s  disease  in  the  country.  In this  cohort  other 
common  etiological  factors  were  coagulopathies, 
unknown  etiology,  oral  contraceptive  use  and  other 
inflammatory diseases.
13 On the other hand, data from 
Europe depicts the rarity of BD as an etiological factor 
of CVT, there were only 6 patients with BD among 624 
patients registered in the ISCVT.
3
Interestingly,  however,  a  small  CVT  series  from 
Lebanon did not have any patients with BD, among 16
cases.
14 This  might  be  reflecting  a  selection  bias,  as 
discussed below.
Table 1. Diagnostic criteria for Behçet’s disease (International Study Group for Behçet’s Disease, 1990)
Reccurrent oral aphtae: at least three times in a year
Plus any two of 
genital ulcerations: active lesion or scar
skin lesions: erythema nodosum, foliculitis, other ulcerations
eye involvement: anterior or posterior uveitis, or retinal vasculitis
positive pathergy test: skin hyper-reactivity to pinprick (sterile pustule formed in 24-48 h)Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
In another CVT series including only patients with 
cortical  or  deep  vein  thrombosis,  excluding  patients 
with  dural  sinus  thrombosis  from  Turkey,  similar 
frequencies  of  etiologies  to  those  reported  from  the 
West with few CVT patients with BD was reported.
15
Albeit small in size, in this series the distribution of 
etiological  factors  causing  CVT  among  hormonal 
factors, malignancy, genetic thrombophilia, infections, 
hematological  disorders,  vasculitis  and  interventions
was more or less similar to the largest cohort reported 
from  the  rest  of  the  world  composed  mostly  of 
Nortwestern European countries.
3,15 Most probably, the 
inclusion  of patients  with  only  cortical or  deep  vein 
thrombosis  was  the  reason  for  this  difference, 
supporting the clinical presentation differences in CVT 
patients  with  and  without  BD  emphasized  in  the 
comparative  study.
12 In  a  previous  study  of  venous 
thrombosis  from  Turkey,  it  was  concluded  that  BD 
may  be  taking  part  together  with  other  etiologies  in 
most of the cases;
16 in that case when another etiology 
is  found  BD  might  have  been  overlooked  in  some 
centers not so familiar with BD. On the other hand, our 
center is a nationwide tertiary center with a specialized 
multidisciplinary BD clinic and the frequency of CVT 
due to BD in our center may be over-represented due to 
a selection bias. However, the prevalence of BD was 
estimated  as  42/10,000  (95%  CI,  34-51/10,000)  in 
Istanbul, Turkey, supporting the notion that Turkey has 
the  highest  prevalence  rate of  the  disease  in  the 
world.
17 Therefore it is not surprising to encounter BD 
as a frequent etiology in  CVT in  the series reported 
from  our  center  in  Istanbul.  Furthermore,  a  recent 
review including CVT patients with BD mainly from 
countries  in  the  Mediterranean  region  showed  that 
CVT  incidence in  BD was about  3 per  1000 person 
years.
18
As  mentioned  above  ¾  of  the  patients in  ISCVT 
were women and the most common risk factor was oral 
contraceptive use.
3 However, in BD which is slightly 
more  prevalent among  males,  serious  organ 
involvement  is  significantly  more  frequent  in  males 
and this gender predisposition is also seen in cerebral 
venous  thrombosis  patients  with  BD.
12 In  the  study 
where a direct comparison was made in CVT patients 
with  and  without  BD,  CVT  due  to  BD  was 
significantly  more  common  among  male  patients.  In 
the same study the mean age was 26 in the non-BD 
group and 39 in the BD group, resulting in a significant 
difference.  However  in  the  largest  CVT  series 
published  mean  age  was  37  for  CVT patients, 
comparable to that seen in BD patients with CVT.
3
The rarity of acute  presentation  with neurological 
deficits and seizures in patients with BD may preclude 
the inclusion of these patients in other CVT series.
7 In 
CVT clinical features differ according to the location 
and the extent of the occlusion in the sinuses and veins 
and  the  course  of  the  underlying  disease  process.  A 
slowly progressing dural sinus thrombosis that does not 
affect the cortical venous circulation may present with 
isolated headache and normal neurological examination 
findings.  These  patients  may  be  misdiagnosed  as 
pseudotumor  cerebri.  However  an  acute  clinical 
presentation  with  focal  neurological  deficits  and 
seizures  can  be  readily  diagnosed  as  CVT  with 
appropriate imaging techniques. CVT in  BD patients 
mostly  presents  with  signs  of  isolated  intracranial 
hypertension and venous infarction rarely develops.
12
As a consequence in CVT due to BD patients usually 
have  an  insidious  onset,  they  present  usually  with 
headache  as  the  only  symptom  and  the  neurological 
examination is normal or only papilledema or lateral 
gaze paresis indicative of intracranial hypertension is 
found.  
In the past, CVT used to be considered a condition 
with bad prognosis, but currently CVT is considered to 
be a relatively more benign condition  with  mortality 
rates below 10%.
19-23 According to the limited follow-
up data on CVT with and without BD there were no 
significant  differences  between  the  two  groups  on 
outcome.
12 A  greater  tendency  for  recurrence  was 
found in patients with BD.
12 A cytopathological study 
on  BD  CVT  cases  is  not  available  however  former 
autopsy  findings  on  pulmonary  arterial  thrombosis 
suggests  an  inflammatory  process  underlying  the 
thrombosis.
24 This  finding  may  explain  the  chronic 
course of the thrombotic process in CVT due to BD 
leading to the mentioned clinical differences. 
The  treatment  of  CVT  mainly  comprises  of 
anticoagulation,  with  subcutaneous  fractionated 
heparin  at  the  acute  stage,  and  6  months  of  oral 
anticoagulation,  afterwards.
25 However,  since  the 
thrombosis  of  BD  is  considered  an  inflammatory 
process rather than a procoagulant process,
26 treatment 
of these cases may vary. Although treatment of CVT 
due  to  BD  is  still  debated  and  Class  I  evidence  is 
lacking
27 our approach is to use only steroids, instead 
of anticoagulants, as also suggested by EULAR task 
force.
28 In such cases we usually give 5 consecutive 
days of IV methylprednisolone followed by a slow oral 
taper.
29 In recent years we also tend to add long-term 
azathioprine to  prevent recurrences or  other  vascular 
complications that could be seen in those patients.
27 In 
intractable  cases  or  repetitive  CVTs  due  to  BD, 
anticoagulants  may  be  added  to  steroids;  but Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
anticoagulants should never be used alone.
29 It should 
be kept in mind that pulmonary aneurysms should be 
ruled out before initiating any anticoagulant treatment 
in patients with BD. 
Due to the scarcity of data on CVT and inherited 
and acquired causes in countries of the south-eastern 
Mediterranean region a comparison with northwestern 
Mediterranean  region  is  quite  difficult  to  make. 
However,  one  report  emphasized  the  occurrence  of 
CVT  due to  BD in  Turkey which  deserves attention 
both  in terms of the differences in  demographic  and 
clinical  features  and  possibly  the  treatment  options. 
Therefore,  in  patients  with  CVT  from  southeast 
Mediterranean  region,  BD  should  be  kept  in  mind 
especially if the patient is male, and if no other risk 
factor  can  be  identified.  BD  should  always  be 
questioned since multi-etiology cases are not very rare. 
A multi-national and multi-center prospective analysis 
of the CVT cases in south-east Mediterranean region 
seems to be worthwhile in the near future.
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